



## **Olema Oncology Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022**

March 8, 2022

SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- [Olema Pharmaceuticals, Inc.](#) ("Olema" or "Olema Oncology," Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers, today announced plans to present two posters related to nonclinical data for OP-1250, a potent, oral complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held April 8-13, 2022.

Details of the poster presentations are as follows:

**Title:** Precision run-on sequencing (PRO-seq) analysis of a treatment time course in ER+ breast cancer cell lines reveals the transcriptional changes underlying response to complete estrogen receptor antagonist (CERAN) OP-1250

**Abstract:** 5375

**Session Category:** Experimental and Molecular Therapeutics

**Session Title:** Mechanisms of Drug Action

**Session Type:** E-Poster

**Title:** OP-1250 prevents tumor spread in a model of metastatic mutant ER $\alpha$ + breast cancer

**Abstract:** 1618

**Session Category:** Tumor Biology

**Session Title:** Cell Line and Animal Models

**Session Date and Time:** Monday, April 11, 2022, 1:30 p.m. - 5:00 p.m. CT

**Location:** New Orleans Convention Center, Exhibit Halls D-H, Poster Section 11

The poster presentations will be available on Friday, April 8 at 1:00 p.m. ET on the conference meeting platform and on Olema's website under the [Science](#) section.

### **About Olema Oncology**

Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women's cancers. Olema's lead product candidate, OP-1250, is an orally-available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1/2 clinical trial, and in Phase 1b combination with palbociclib, in patients with recurrent, locally advanced, or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.

Contact: Eva Stroynowski Vice President, Communications and Investor Relations [eva@olema.com](mailto:eva@olema.com)